SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results

VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 —— Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91 million in aggregate milestones as…

TOVX
SquawkNews Desk

Related stories

AAON Expands Credit Facility to Up to $1.2 Billion AAON said it refinanced and expanded its credit facility to up to $1.2 billion. M impact | EQUITY | Nov 12, 2026, 03:11 PM UTC Hyperliquid Nvidia Perpetual Futures Reach Nearly $2 Billion in 24-Hour Volume The Nvidia-linked contract ranked second on Hyperliquid, behind Bitcoin perpetual futures. M impact | EQUITY | Nov 12, 2026, 03:10 PM UTC Page Industries Shares Plunge 13% as Higher Raw-Material Costs Hit Q2 Profitability Page Industries shares fell 13% to Rs. 31,850, their lowest level since April, as investors reacted to second-quarter profitability pressure from higher raw-material costs. M impact | EQUITY | Nov 12, 2026, 03:09 PM UTC Maersk Opens Montevideo Logistics Facility With Investment Above USD 20 Million Maersk opened a logistics facility in Montevideo, investing more than USD 20 million. M impact | EQUITY | Nov 12, 2026, 03:07 PM UTC US Neocloud Stocks Fall Up to 16% After Huang Resigns as Nvidia CEO Nebius led losses in early US trading as investors assessed the implications of Jensen Huang's resignation from Nvidia. M impact | EQUITY | Nov 12, 2026, 03:06 PM UTC Southern Company Announces $1.75 Billion Mandatory Convertible Southern Company announced a $1.75 billion mandatory convertible. Its shares edged down. M impact | EQUITY | Nov 12, 2026, 03:05 PM UTC